Non-organic Solvent Method of Extracting N-Acetyl glucosamine from a fermentation broth

Wellesley Therapeutics Inc.是一家总部位于多伦多的制药公司，目前以商品名Ultimate Glucosamine®和Villicote®销售两种含有GlcNAc （GlcNAc）的产品。韦尔斯利目前的GlcNAc净化工艺需要使用多步骤、有机溶剂、提取和沉淀方法。这种方法成本高，对环境有负面影响，并且存在安全问题-需要昂贵的防爆处理。Wellesley正在寻求与Seneca的生物科学与应用化学学院（BSAC）合作，采用绿色化学方法进行产品回收和净化。该方法将结合GlcNAc的物理溶解度特性，以消除有机溶剂相关沉淀的需要。

Wellesley Therapeutics Inc., is a Toronto-based pharmaceutical company, currently marketing two GlcNAc (GlcNAc) containing products under the trade name Ultimate Glucosamine® and Villicote®. Wellesley's current purification process for GlcNAc requires the use of a multistep, organic solvent based, extraction and precipitation methodology. This method is costly, has negative effects on the environment and has safety concerns - expensive explosion proof processing is required. Wellesley is looking to collaborate with Seneca's School of Biological Sciences and Applied Chemistry (BSAC) to adopt a green chemistry approach to product recovery and purification. This approach will incorporate the physical solubility properties of GlcNAc to eliminate the need for organic solvent associated precipitation. Wellesley is engaged in the clinical development of GlcNAc for multiple sclerosis, muscular dystrophy and Parkinson's disease. Claims for the treatment of these indications will require Wellesley to file a new drug application. This application requires a detailed description of physical and chemical manufacturing processes and controls for production. The experimental work carried out at Seneca will translate to a detailed description and rationale for the intended commercial production methods